NEW YORK, Aug. 22 – Sequitur said on Wednesday it has licensed its antisense technology to Rigel Pharmaceuticals for use in functional genomics research.

The agreement calls for Sequitur, based in Natick, Mass., to provide Rigel with antisense compounds and methods for selecting and transfecting DNA sequences. In return, Rigel, based in South San Francisco, Calif., will pay research support, charges for antisense compounds, and licensing fees.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.